An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Forma Therapeutics (NASDAQ: FMTX) announced a commitment of $1M for formabridge grants to support programs aiding the transition from pediatric to adult care in sickle cell disease (SCD). A recent survey revealed that 62% of patients find this transition challenging, with 73% of physicians noting a lack of guidelines. The new resource hub aims to provide essential information for patients and caregivers. Forma's efforts are directed at addressing significant care gaps during this crucial transition period, aiming for improved health outcomes.
Positive
Commitment of $1M for formabridge grants to support SCD transition programs.
Launch of a new resource hub for patients and caregivers.
Robust survey reveals critical insights into patient and physician challenges, guiding future initiatives.
Negative
62% of patients reported the transition experience as difficult.
73% of physicians acknowledged insufficient transition guidelines.
Forma SCD Trend Report: The State of Transition survey reveals 62% of patients found the transition experience “moderately or very challenging” and 73% of physicians state there are a lack of transition guidelines and protocols in their practice or institution
formabridge grants will support programs and research initiatives to address unmet needs in transition from pediatric to adult care in sickle cell disease
New transition resource hub www.formabridge.comfor patients and caregivers launched at the 63rdAmerican Society of Hematology Annual Meeting and Exposition
WATERTOWN, Mass.--(BUSINESS WIRE)--
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers, today announced formabridge. Through formabridge grants, Forma has committed $1M in funding for promising and innovative initiatives that address unmet needs in transition from pediatric to adult care in SCD. Funding will be provided to researchers, healthcare institutions, patient and community organizations based on specific criteria. Proposals will be reviewed by a panel of Forma personnel and external advisors with expertise in the challenges impacting transition in SCD. Grants will be awarded to proposals that have the greatest potential to improve patient care in the first half of 2022.
“We’ve been moved by our discussions with the SCD community, particularly as we learn more about how patients experience the disease as they age out of the pediatric system,” said Frank Lee, president and chief executive officer of Forma. “Though great strides have been made to reduce pediatric mortality and morbidity in SCD, the period of transition leads to significant care gaps, and sadly is often marked by increased hospitalizations and mortality. Successful transition will require a collective and concerted effort to change the future of SCD. Our hope is that formabridge will play an impactful role in securing a safer and healthier future for people living with this disease.”
Forma’s inaugural SCD Trend Report: The State of Transition provides insights from a robust survey of patients, caregivers and physicians. The report highlights obstacles patients face during transition and identifies areas where patients and physicians have differing views. The report will be published annually and is intended to facilitate discussion on opportunities to better support people living with SCD, along with opportunities to support key systemic and policy changes. Key findings in the report include:
62% of patients found their overall transition experience “moderately or very challenging”
78% of patients report discrimination and stigma prevent them from receiving the SCD care they need
73% of physicians agree there is a lack of transition guidelines and protocols in their practice or institution
“Increasing the understanding of challenges faced by both patients and health care providers during transition from pediatric to adult care is fundamental to fixing the problem,” said Dr. Nirmish Shah, a hematologist and the director of the Sickle Cell Transition Program at Duke University. “While there are no immediate or easy answers, my hope is that funding and other resources from formabridge can help to move the needle for people living with SCD.”
www.formabridge.com is intended to serve as a resource hub for patients during transition. Through collaboration with patient advocacy groups throughout the United States, the site offers educational, credible and actionable information to help the community navigate Medicaid, disability benefits, and more, and is curated for easy access and understanding. The site also includes inspirational educational videos to engage and support patients during the transition process.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.
Forward-looking Statements
This press release may contain forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “will,” “could,” “would,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavors,” “potential,” “continue,” “target” or the negative of such words or other similar expressions can be used to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The express or implied forward-looking statements included in this press release, including the potential benefit and impact of formabridge on sickle cell disease patients, are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption “Risk Factors” in Forma’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Forma believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Forma nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release represents Forma’s views only as of the date on which it was made. Forma undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
